
The company incurred a net loss of approximately $9,705,000 and $13,045,000 during the nine months ended September 30, 2026 and 2025, respectively. As of September 30, 2026, the company had
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| LTRN | Lantern Pharma | 0.25 | -2.78 | -91.89% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.25 | -91.89% |

The company incurred a net loss of approximately $9,705,000 and $13,045,000 during the nine months ended September 30, 2026 and 2025, respectively. As of September 30, 2026, the company had

In a regulatory filing, Lantern Pharma (LTRN) announced that on November 15, Panna Sharma resigned as President and Chief Executive Officer of the company, effective as of November 15. Sharma

In a regulatory filing, Lantern Pharma (LTRN) announced that on November 13, 2026, the company received a written notice from The Nasdaq Stock Market LLC notifying the company that, for

Rodman & Renshaw downgraded Lantern Pharma (LTRN) to Neutral from Buy and removed the firm’s prior price target following the resignation of President and CEO Panna Sharma. Sharma’s departure outweighs

Lantern Pharma ( ($LTRN) ) has released a notification of late filing. Lantern Pharma Inc. filed Form 12b-25, a notification of late filing, for its Form 10-Q (Quarter Report) covering

Lantern Pharma (LTRN) and its wholly owned subsidiary Starlight Therapeutics announced the publication of Phase 1a clinical data for LP-184 in patients with recurrent GBM. LP-184 is being developed as

Lantern Pharma, Inc. (LTRN) is scheduled to report 3rd quarter earnings on 11/11/2026. Regarding Q3 estimates, Wall Street analysts expect Lantern Pharma, Inc. to post earnings of -$0.35 per share.

Lantern Pharma (LTRN) announced that it has received regulatory and IRB approvals in Taiwan to open the next stage of its Phase 2 HARMONIC trial of LP-300. The Taiwan Food

Lantern Pharma ( ($LTRN) ) has issued an update. On September 25, 2026, Lantern Pharma Inc. disclosed that it had received a notice from Nasdaq stating the company was no

The latest update is out from Lantern Pharma ( ($LTRN) ). Lantern Pharma Inc., a clinical-stage, AI-native biopharma focused on precision oncology therapies through its RADR machine-learning platform and a
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 11, 2027TBA | $4.51M | $-0.41 | $0.00 | 0.02 | -0.21 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.